# Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

> **NCT00092287** · PHASE3 · TERMINATED · sponsor: **Ipsen** · enrollment: 4 (actual)

## Conditions studied

- Malignant Carcinoid Syndrome

## Interventions

- **DRUG:** lanreotide Autogel (somatostatin analogue)
- **DRUG:** Sandostatin long acting release (LAR) Depot (somatostatin analogue)

## Key facts

- **NCT ID:** NCT00092287
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00092287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00092287, "Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00092287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*